Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) announced that it is conducting a strategic review of its business to determine how to optimally deploy its capital to maximize shareholder return. On a preliminary unaudited basis, as of December 31, 2023, Aclaris? aggregate cash, cash equivalents and marketable securities was approximately $182 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.215 USD | +1.25% | -0.41% | +15.71% |
Mar. 19 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
Feb. 27 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.71% | 85.52M | |
+2.30% | 42.75B | |
+47.70% | 41.61B | |
+11.48% | 41.34B | |
-12.36% | 26.59B | |
+8.46% | 25.49B | |
-23.08% | 18.12B | |
+30.86% | 12.24B | |
-1.34% | 11.76B | |
+8.45% | 11B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Conducts Strategic Review of Business